Abstract Background High-throughput methodologies such as microarrays and next-generation sequencing are routinely used in cancer research, generating complex data at different omics layers. The effective integration of omics data could provide a broader insight into the mechanisms of cancer biology, helping researchers and clinicians to develop personalized therapies. Results In the context of CAMDA 2017 Neuroblastoma Data Integration challenge, we explore the use of Integrative Network Fusion (INF), a bioinformatics framework combining a similarity network fusion with machine learning for the integration of multiple omics data. We apply the INF framework for the prediction of neuroblastoma patient outcome, integrating RNA-Seq, microarray ...
Recent technological advances and international efforts, such as The Cancer Genome Atlas (TCGA), hav...
BACKGROUND: More than 90% of neuroblastoma patients are cured in the low-risk group while only le...
International initiatives such as the Molecular Taxonomy of Breast Cancer International Consortium a...
High-throughput methodologies such as microarrays and next-generation sequencing are routinely used ...
Background: One of the main current challenges in computational biology is to make sense of the huge...
Abstract Background Neuroblastoma is a heterogeneous disease with diverse clinical outcomes. Current...
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
BACKGROUND: Neuroblastoma is one of the most common types of pediatric cancer. In current neurobl...
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
Abstract Background More than 90% of neuroblastoma patients are cured in the low-risk group while on...
AbstractThere have been several reports about the potential for predicting prognosis of neuroblastom...
Recent technological advances and international efforts, such as The Cancer Genome Atlas (TCGA), hav...
BACKGROUND: More than 90% of neuroblastoma patients are cured in the low-risk group while only le...
International initiatives such as the Molecular Taxonomy of Breast Cancer International Consortium a...
High-throughput methodologies such as microarrays and next-generation sequencing are routinely used ...
Background: One of the main current challenges in computational biology is to make sense of the huge...
Abstract Background Neuroblastoma is a heterogeneous disease with diverse clinical outcomes. Current...
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
BACKGROUND: Neuroblastoma is one of the most common types of pediatric cancer. In current neurobl...
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and poor outcomes....
Abstract Background More than 90% of neuroblastoma patients are cured in the low-risk group while on...
AbstractThere have been several reports about the potential for predicting prognosis of neuroblastom...
Recent technological advances and international efforts, such as The Cancer Genome Atlas (TCGA), hav...
BACKGROUND: More than 90% of neuroblastoma patients are cured in the low-risk group while only le...
International initiatives such as the Molecular Taxonomy of Breast Cancer International Consortium a...